TWI863271B - 用於調節ｃｏｔ之化合物之固體形式 - Google Patents

用於調節ｃｏｔ之化合物之固體形式 Download PDF

Info

Publication number
TWI863271B
TWI863271B TW112117450A TW112117450A TWI863271B TW I863271 B TWI863271 B TW I863271B TW 112117450 A TW112117450 A TW 112117450A TW 112117450 A TW112117450 A TW 112117450A TW I863271 B TWI863271 B TW I863271B
Authority
TW
Taiwan
Prior art keywords
formula
degrees
reflections
solid form
inhibitors
Prior art date
Application number
TW112117450A
Other languages
English (en)
Chinese (zh)
Other versions
TW202400161A (zh
Inventor
爾內斯特 A 卡拉
盈盈 陳
大輔 齋藤
Original Assignee
美商基利科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商基利科學股份有限公司 filed Critical 美商基利科學股份有限公司
Publication of TW202400161A publication Critical patent/TW202400161A/zh
Application granted granted Critical
Publication of TWI863271B publication Critical patent/TWI863271B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112117450A 2022-05-12 2023-05-11 用於調節ｃｏｔ之化合物之固體形式 TWI863271B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263341289P 2022-05-12 2022-05-12
US63/341,289 2022-05-12

Publications (2)

Publication Number Publication Date
TW202400161A TW202400161A (zh) 2024-01-01
TWI863271B true TWI863271B (zh) 2024-11-21

Family

ID=86710687

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112117450A TWI863271B (zh) 2022-05-12 2023-05-11 用於調節ｃｏｔ之化合物之固體形式

Country Status (9)

Country Link
US (1) US20240174702A1 (enExample)
EP (1) EP4522268A1 (enExample)
JP (1) JP2025515671A (enExample)
KR (1) KR20250008904A (enExample)
CN (1) CN119137131A (enExample)
AU (1) AU2023269038A1 (enExample)
CA (1) CA3252705A1 (enExample)
TW (1) TWI863271B (enExample)
WO (1) WO2023220123A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI915558B (zh) 2019-06-14 2026-02-21 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
EP4126862B1 (en) 2020-04-02 2025-05-21 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound
TW202523303A (zh) * 2023-12-11 2025-06-16 美商基利科學股份有限公司 用於治療發炎性腸道疾病之化合物及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020252151A1 (en) * 2019-06-14 2020-12-17 Gilead Sciences, Inc. Cot modulators and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020252151A1 (en) * 2019-06-14 2020-12-17 Gilead Sciences, Inc. Cot modulators and methods of use thereof

Also Published As

Publication number Publication date
JP2025515671A (ja) 2025-05-20
EP4522268A1 (en) 2025-03-19
WO2023220123A1 (en) 2023-11-16
AU2023269038A1 (en) 2024-11-28
CN119137131A (zh) 2024-12-13
TW202400161A (zh) 2024-01-01
KR20250008904A (ko) 2025-01-16
US20240174702A1 (en) 2024-05-30
CA3252705A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
TW202400161A (zh) 用於調節ｃｏｔ之化合物之固體形式
EP3962602B1 (en) Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
US12459908B2 (en) Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties
JP6944462B2 (ja) チエノピリミジンジオンａｃｃ阻害剤の固体形態およびその生成のための方法
TWI453017B (zh) （２ｓ）－２－（｛３’－氯－４’－〔（２，２－二甲基吡咯烷－１－基）羰基〕－５－氟聯苯－２－基｝氧）丙酸及其藥學上可接受之鹽類
JP2021091736A (ja) Ａｃｃ阻害剤およびその固体形態を調製するためのプロセス
US12503454B2 (en) LPA receptor antagonists and uses thereof
US20230381132A1 (en) Novel compounds
US20240010606A1 (en) Fumarate derivatives and their medical use
US20230399289A1 (en) Itaconic acid derivatives
KR20190002468A (ko) N-[2-(3-히드록시-3-메틸부틸)-6-(2-히드록시프로판-2-일)-2h-인다졸-5-일]-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 결정질 형태
CN118541360A (zh) Lpa受体拮抗剂及其用途
US20240245691A1 (en) 2-methylene-4-oxo-butanoic acid derivatives for the treatment of inflammation
US20260138973A1 (en) Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response
US20250333408A1 (en) Pyrimid-2-yl-pyrazole compounds as irak inhibitors
US20220177467A1 (en) Janus Kinase (JAK) Family Inhibitor, Preparation of Same, and Applications Thereof
JP2015529254A (ja) 喘息における気道の過敏症及び炎症を制御するための新規なｇａｂａａアゴニスト及び使用方法
HK40119474A (en) Solid forms of a compound for modulating cot
CN121358738A (zh) 调节irak4的化合物的盐和固体形式
US20230312568A1 (en) Tricyclic irak inhibitors